Targeting, Attacking, and Eradicating Cancers®
Received BeiGene drug support for the BAL0891 combination trial
Acquired a Japanese patent for the SJ-600 Series
Submitted a clinical IND for BAL0891 in AML to the U.S. FDA
All the pipelines of Sillajen accepted for presentation at AACR 2024
Presented clinical analysis of Pexa-Vec at ASCO 2024
Entered a joint research agreement with Qureator on BAL0891
Published SJ-600 Series preclinical results in JITC
Received MFDS IND approval for the BAL0891 Phase 1 clinical trial
Expanded R&D center
Pexa-Vec combination therapy for renal cell carcinoma accepted for a poster at the 2023 ESMO meeting
Presented the CSR for the Phase 1b/2a trial of the Pexavec combination therapy
Relocated headquarters to Sogong-dong, Jung-gu
Appointed Jae-kyung Kim as CEO
In-licensed MCI substance BAL0891 from Basilea Pharmaceutical
Presented BAL0891 preclinical data at the 2022 EORTC-NCI-AACR meeting
FDA approved a plan to change the phase 1b/2a clinical trial of Pexa-vec+Cemiplimab in RCC
Changed the largest shareholder to M2N Co., Ltd.
Appointment of Jang Dong-taek as a CEO
Start administering to patients in the phase 1b/2 clinical trial in melanoma with Lee's Pharmaceuticals, Inc.
Establishment of Commerce Business Group
Changed the headquarter(Jung-gu, Seoul, Republic of Korea)
Announced Interim clinical analysis of RCC (Renal Cell Carcinoma) in AACR (American Cancer Research Society) ; 16 Patients treated with Pexa-Vec (IV) and Cemiplimab - CR in 1 Patient, PR in 5 Patients, and 75% DCR
Construction of the COVID-19 candidate vaccines and small animal preclinical study
Neoadjuvant Study in Prostate Cancer, Multi-Center trials including Royal Melbourne Hospital in VIC, Australia ; Approved in HREC and plan to notify TGA
Pexa-Vec, FDA Orphan Drug Designation(ODD) to stage IIB-IV Melanoma
Pexa-Vec combined with PD-L1 monoclonal antibody clinical trial in metastatic Melanoma, partnership with LeesPharm ; Approved in China Regulatory Authority and expects recruitment
Poster presentation on Phase 1 interim safety data of Pexa-Vec + Imfinzi clinical study at Gastrointestinal Cancers Symposium (GI ASCO)
Poster presentation on safety data of the Phase 1 dose-escalation clinical trial of Pexa-Vec + Yervoy, at European Society for Medical Oncology (ESMO) Immuno-Oncology
IND approved by Therapeutic Goods Administration on Phase 1 study of Pexa-Vec + Libtayo
Poster presentation on Pexa-Vec as a neoadjuvant therapy at American Society of Clinical Oncology (ASCO)
First patient enrollment in the US in the Phase 1 study of Pexa-Vec + Libtayo
Presentation on pre-clinical data in Renal Cell Carcinoma (RCC) at American Association for Cancer Research Annual Meeting (AACR)
Poster presentation on clinical data in Renal Cell Carcinoma (RCC) at International Oncolytic Virus Conference (IOVC)
Stretched out additional vaccinia virus related patents in 13 European territories
Approval by Ministry of Food and Drug Safety (MFDS) of South Korea to commence the Phase 1 clinical trial of Pexa-Vec + Libtayo in RCC
Poster presentation on RCC clinical data at Genitourinary Cancers Symposium (GU ASCO)
Expanded strategic manufacturing collaboration for JX-970
Collaboration with National Cancer Institute of the US for developing Pexa-Vec in combination with immune checkpoint inhibitors
Collaboration with Regeneron Pharmaceuticals for developing Pexa-Vec in combination with immune checkpoint inhibitors.
SillaJen was listed on KOSDAQ
SillaJen was selected by the government of South Korea as the major developer for the project of “Global State-of-the-art technology development for biomedical products"
SillaJen acquired Jennerex, Inc., the global leader in oncolytic immunotherapeutics
Jennerex was an early leader in the oncolytic virus field. Jennerex researchers showed that Pexa-Vec acted in three distinct ways to attack cancer : by infecting and killing cancer cells, by cutting off the blood supply totumors, and by activating the body’s own immune system to fight cancer
Jennerex initiated Pexa-Vec Phase 2b clinical trial (HEP018) for Liver Cancer
Jennerex initiated Pexa-Vec Phase 2a clinical trial (HEP007)
Jennerex completed Pexa-Vec Phase 1 clinical trial (HEP001)
